This Slide: #48 of 100 |
Slide #48. Clinical Genomics Technologies Pty Ltd — Quest Diagnostics Enterix colorectal cancer screening test business
Acquirer:
Clinical Genomics Technologies Pty Ltd
Acquiree:
Quest Diagnostics Enterix colorectal cancer screening test business (NYSE:DGX)
Details:
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that on September 30, 2013 it completed the sale of its Enterix colorectal cancer screening test business to Clinical Genomics Technologies Pty Ltd., an Australian life sciences company. Terms of the transaction were not disclosed.
Open the DGX Page at The Online Investor »
|
Open the DGX Page at The Online Investor (in a new window) »
Free DGX Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Buy (2.53 out of 4) 6th percentile
(ranked lower than approx. 94% of all stocks covered)
Analysts' Target Price: DGX Stock Forecast Based on Zacks ABR data; powered by Xignite |